TY - JOUR TT - C-Reactive Protein Levels in Women with Polycystic Ovarian Syndrome and Healthy Controls AU - Temur, Muzaffer AU - Yılmaz, Özgür AU - Küme, Tuncay AU - Alper Karas, Çiğdem AU - Kelekçi, Sefa AU - Kılıç Öztürk, Yasemin PY - 2017 DA - December DO - 10.21763/tjfmpc.359835 JF - Turkish Journal of Family Medicine and Primary Care JO - TJFMPC PB - Aile Hekimliği Akademisi Derneği WT - DergiPark SN - 1307-2048 SP - 265 EP - 270 VL - 11 IS - 4 KW - Polycystic ovarian syndrome KW - C-reactive protein KW - inflammation N2 - Aim/background: Although,pathophysiology of polycystic ovarian syndrome has not been fully understood,insulin resistance may have a pivotal role in this condition. It has beensuggested that subclinical inflammation is strongly related to both insulinresistance and obesity associate metabolic disorders. In this study, we aimedto evaluate the serum levels of C-reactive protein which has been determined asan insulin resistance related inflammatory marker and investigate to itspotential role the polycystic ovarian syndrome in our study population. Methods: Forty women with polycysticovarian syndrome and forty age and body mass index matched healthy controlswere retrospectively evaluated in this study. Serum fasting glucose, insulin,C-reactive protein and total testosterone concentrations were assessed. Results: Both serum C-reactive protein(1.14±1.86 mg/L vs. 3.56±4.69mg/L; p= 0.004) and total testosteroneconcentrations (p=0.011) were higher in polycystic ovarian syndrome group.C-reactive protein levels significantly and positive correlated with bodyweight, body mass index and waist circumference (p<0.05). In the linearregression model, polycystic ovarian syndrome was defined as a dependentvariable and hs-CRP was determined as a independent variable. According to thisanalysis C-reactive protein associated with polycystic ovarian syndrome (β=0.326, R2 = 0.106 and p= 0.003) Conclusion:Several inflammatory molecules associate with both insulin resistance andobesity related cardio metabolic disorders. However, there are some conflictingresults in relationship between polycystic ovarian syndrome and inflammatorymolecules including C-reactive protein. Therefore, advanced studies need toexplain the potential role of the C-reactive protein in polycystic ovarian syndrome. Amaç/Giriş:Polikistik over sendromunun (PKOS) patogenezi tam olarakanlaşılamamış olmakla birlikte insülin direncinin bu hastalıkta önemli bir rolesahip olabileceği bildirilmiştir. Subklinik inflamasyonun insulin direnci veobezite ile ilişkili metabolik bozukluklarda önemli bir rol oynadığıdüşünülmektedir. Bu çalışmada incelediğimiz populasyonda PKOS’lu ve sağlıklıkadınlar arasında bir inflamatuar belirteç olan C-reaktif protein serumdüzeylerini değerlendirerek polikistik over sendromundaki yerinideğerlendirmeyi amaçladık. Yöntem: Polikistikover sendromu olan 40 kadın ile vücut kitle indeksi ve yaş açısındaneşleştirilmiş olan 40 sağlıklı kadın geriye dönük olarak incelendi. Serum açlıkglukoz, insulin, C-reaktif protein (CRP) ve total testosteron düzeylerideğerlendirildi. Bulgular: SerumC-reaktif protein (1.14±1.86 mg/L’e karşın 3.56±4.69mg/L; p= 0.004) ve serumtotal testosteron konsantrasyonu (p=0.011) polikistik over sendromlu kadınlardaanlamlı olarak daha yüksekti. Serum C-reaktif protein ile vücut ağırlığı, vücutkitle indeksi ve bel çevresi arasında anlamlı pozitif korelasyon saptandı(p<0.05). Polikistik over sendromunun bağımlı değişken, C-reaktif proteininise bağımsız değişken olarak tasarlandığı lineer regresyon modeli’ninsonuçlarına göre C-reaktif proteinin polikistik over sendromu ile istatistikselolarak anlamlı seviyede birliktelik gösterdiği saptandı (β= 0.326, R2= 0.106 ve p= 0.003) Sonuç: Pek çokinflamatuar molekül insulin direnci ve obezite ile ilişkili metabolik vekardiyovasküler bozukluklar ile birliktelik gösterir. Ancak polikistik over sendromuile C-reaktif proteini de içeren inflamatuar moleküller arasındaki ilişkiye aitveriler birbirleri ile tam olarak örtüşmemektedir.  Bundan dolayı ileri çalışmalarla C-reaktifproteinin polikistik over sendromundaki rolünün aydınlatılması gereklidir.  CR - 1. Mukherjee S, Maitra A. Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome. Indian J Med Res. 2010; 131:743-60. CR - 2. Majumdar A, Singh TA. Comparison of clinical features and health manifestations in lean vs. obese Indian women with polycystic ovarian syndrome. J Hum Reprod Sci. 2009; 2:12-17. CR - 3. Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators Inflamm. 2010; 2010:758656 CR - 4. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome.Eur J Endocrinol. 2010; 162:193-212. CR - 5. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107:363-369. CR - 6. Oemrawsingh RM, Cheng JM, Akkerhuis KM, Kardys I, Degertekin M, van Geuns RJ et al. High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention. EuroIntervention. 2016 Jun 20;12(3):345-51 CR - 7. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2013;12: 4565–4592 CR - 8. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412–419 CR - 9. El-Mesallamy HO, Abd El-Razek RS, El-Refaie. TA.Circulating high-sensitivity C-reactive protein and soluble CD40 ligand are inter-related in a cohort of women with polycystic ovary syndrome.Eur J Obstet Gynecol Reprod Biol. 2013; 168:178-182. CR - 10. Sumithra NU, Lakshmi RL, Leela Menon N, Subhakumari KN, Sheejamol VS. Evaluation of oxidative stress and hsCRP in polycystic ovarian syndrome in a tertiary care hospital.Indian J Clin Biochem. 2015; 30:161-166. CR - 11. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Müller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance.J Clin Endocrinol Metab. 2005; 90:6014-6019 CR - 12. Ganie MA, Hassan S, Nisar S, Shamas N, Rashid A, Ahmed I, et al. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2014; 30:781-784. CR - 13. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001; 86:2453-2455. CR - 14. Amato G, Conte M, Mazziotti G, Lalli E, Vitolo G, Tucker AT, et al. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles.Obstet Gynecol. 2003;101:1177-1182 CR - 15. Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism. 1999; 48:437-441. CR - 16. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millán JL. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia. 2003; 46:625-633 CR - 17. Chen MJ, Yang WS, Yang JH, Chen CL, Ho HN, Yang YS. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. Hypertension. 2007; 49:1442-1447 CR - 18. Luque-Ramírez M, Martí D, Fernández-Durán E, Alpañés M, Álvarez-Blasco F, Escobar-Morreale HF. Office blood pressure, ambulatory blood pressure monitoring, and echocardiographic abnormalities in women with polycystic ovary syndrome: role of obesity and androgen excess. Hypertension 2014;63:624-629. CR - 19. Kim MJ, Lim NK, Choi YM, Kim JJ, Hwang KR, Chae SJ, et al. Prevalence of metabolic syndrome is higher among non-obese PCOS women with hyperandrogenism and menstrual irregularity in Korea. PLoS One. 2014 Jun 5;9(6):e99252. UR - https://doi.org/10.21763/tjfmpc.359835 L1 - https://dergipark.org.tr/tr/download/article-file/373676 ER -